Nelio Tablets | 
Nelio tablets contain the drug benazapril, which has an effect on the kidneys and blood circulation. Nelio is helpful for dogs with heart failure and for cats with reduced kidney function. Both cats and dogs will often eat Nelio flavoured tablets spontaneously, but they can be given in food if it is easier. They are recommended to be given just once daily
| | | | |
|  | Customers who purchased these items also purchased |   | | Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction 
Company name: Alstoe Ltd
Address: The Industrial Park
Sheriff Hutton
York
YO60 6RZ
Telephone: 01347 878606
Fax: 01347 878333
Email: info@alstoe.co.uk
Website: www.alstoe.co.uk
Presentation
Flavoured, oblong scored beige tablet, divisible into halves. Each tablet contains benazepril (as hydrochloride) 2.30 mg
(equivalent to benazepril hydrochloride 2.5 mg)
Uses
Treatment of chronic renal insufficiency, in cats.
Dosage and administration
Oral administration of 0.46 mg of benazepril per kg and per day, equivalent to 0.50 mg of benazepril hydrochloride per kg and per day, as one administration, whether or not with a meal.
The tablets are flavoured and may be taken spontaneously by cats, but can also be administered directly into the cat's mouth or be given with food if necessary.
Contra-indications, warnings, etc
Do not use in case of known hypersensitivity to ACE inhibitors or to any ingredient of the product.
Benazepril may cause mild, intermittent diarrhea in a small proportion of cats.
In cats with chronic renal insufficiency, benazepril may increase plasma creatinine concentrations at the start of therapy. This effect is related to the therapeutic effect of the product in reducing blood pressure, and therefore is not necessarily a reason to stop therapy in the absence of other signs.
Benazepril reduced erythrocyte counts in normal cats at high doses, but this effect was not observed at the recommended dose during clinical trials in cats with chronic renal insufficiency. As is routine in cases of chronic renal insufficiency, it is recommended to monitor erythrocyte counts during therapy.
Emesis, anorexia, dehydration and lethargy have been reported in rare occasions in cats.
Laboratory studies in rats have shown embryotoxic effects of Benazepril at non-maternotoxic doses (urinary system abnormalities in foetus). Benazepril administered to cats at a daily dose of 10 mg / kg for 52 weeks resulted in the reduction of ovary / oviduct weights. Safety of this product has not been tested in pregnant or lactating queens. Do not use in pregnant or lactating females or in queens intended for breeding.
Blood pressure may be monitored during anesthesia in cats receiving benazepril.
Interactions with potassium preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using benazepril in combination with a potassium sparing diuretic as life threatening reactions are a possibility.
Transient and reversible signs of hypotension may appear in case of accidental overdose. Treatment is symptomatic, involving intravenous infusion with warm isotonic saline.
No evidence of renal toxicity to benazepril has been observed in cats during clinical trials. However, as is routine in cases of renal insufficiency, it is recommended to monitor plasma urea and creatinine levels.
Efficacy and safety of benazepril have not been established in cats of weight less than 2.5 kg.
Pharmaceutical precautions
Do not store above 30°C. Store in original package.
Any half-used tablet should be returned to the opened blister pocket and used for the next administration.
Keep out of reach of children.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Legal category
POM-V
Packaging Quantities
Cardboard box of 10 blisters x 10 tablets
Further information
In cats a 10-fold overdosage daily for one year was asymptomatic.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:Pregnant women should take special care to avoid accidental oral exposure, because ACE inhibitors have been found to affect the unborn child during pregnancy in humans.
Wash hands after use. In case of accidental ingestion by children, seek medical advice immediately and show this label to the doctor.
Marketing authorisation number
Vm 20749/4018.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Alstoe Ltd
Address: The Industrial Park
Sheriff Hutton
York
YO60 6RZ
Telephone: 01347 878606
Fax: 01347 878333
Email: info@alstoe.co.uk
Website: www.alstoe.co.uk
Presentation
Flavoured, clover shaped scored beige tablet, divisible into halves or quarters. Each tablet contains benazepril (as hydrochloride) 4.60 mg
(equivalent to benazepril hydrochloride 5 mg)
Uses
Treatment of chronic renal insufficiency, in cats weighing more than 2.5 kg.
Dosage and administration
Oral administration of 0.46 mg of benazepril per kg and per day, equivalent to 0.50 mg of benazepril hydrochloride per kg and per day, as one administration, whether or not with a meal.
The tablets are flavoured and may be taken spontaneously by cats, but can also be administered directly into the cat's mouth or be given with food if necessary.
Contra-indications, warnings, etc
Benazepril may cause mild, intermittent diarrhea in a small proportion of cats.
In cats with chronic renal insufficiency, benazepril may increase plasma creatinine concentrations at the start of therapy. This effect is related to the therapeutic effect of the product in reducing blood pressure, and therefore is not necessarily a reason to stop therapy in the absence of other signs.
Benazepril reduced erythrocyte counts in normal cats at high doses, but this effect was not observed at the recommended dose during clinical trials in cats with chronic renal insufficiency. As is routine in cases of chronic renal insufficiency, it is recommended to monitor erythrocyte counts during therapy.
Emesis, anorexia, dehydration and lethargy have been reported in rare occasions in cats.
Laboratory studies in rats have shown embryotoxic effects of Benazepril at non-maternotoxic doses (urinary system abnormalities in foetus). Benazepril administered to cats at a daily dose of 10 mg / kg for 52 weeks resulted in the reduction of ovary / oviduct weights. Safety of this product has not been tested in pregnant or lactating queens. Do not use in pregnant or lactating females or in queens intended for breeding.
Blood pressure may be monitored during anesthesia in cats receiving benazepril.
Interactions with potassium preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using benazepril in combination with a potassium sparing diuretic as life threatening reactions are a possibility.
Transient and reversible signs of hypotension may appear in case of accidental overdose. Treatment is symptomatic, involving intravenous infusion with warm isotonic saline.
No evidence of renal toxicity to benazepril has been observed in cats during clinical trials. However, as is routine in cases of renal insufficiency, it is recommended to monitor plasma urea and creatinine levels.
Efficacy and safety of benazepril have not been established in cats of weight less than 2.5 kg.
Pharmaceutical precautions
Do not store above 30°C. Store in original package. Any half-used tablet should be returned to the opened blister and used for the next administration.
Keep out of reach of children.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Legal category
POM-V
Packaging Quantities
Cardboard box of 10 blisters x 10 tablets
Further information
In cats a 10-fold overdosage daily for one year was asymptomatic.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:Pregnant women should take special care to avoid accidental oral exposure, because ACE inhibitors have been found to affect the unborn child during pregnancy in humans.
Wash hands after use. In case of accidental ingestion by children, seek medical advice immediately and show this label to the doctor.
Marketing authorisation number
Vm 20749/4012.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Alstoe Ltd
Address: The Industrial Park
Sheriff Hutton
York
YO60 6RZ
Telephone: 01347 878606
Fax: 01347 878333
Email: info@alstoe.co.uk
Website: www.alstoe.co.uk
Presentation
Flavoured clover shaped scored beige tablet, divisible into halves or quarters. Each tablet contains benazepril (as hydrochloride) 4.60 mg
(equivalent to benazepril hydrochloride 5 mg)
Uses
Treatment of congestive heart failure in dogs weighing more than 2.5 kg.
Dosage and administration
Oral administration: 0.23 mg of benazepril per kg bodyweight per day, equivalent to 0.25 mg of benazepril hydrochloride per kg bodyweight per day, as one administration, with or without a meal.
In case of use of quarters or half tablets: Put the remaining quantity of the tablet back into the blister pocket and use for the next administration.
The dose may be doubled, still administered once daily, if judged clinically necessary and advised by the veterinary surgeon.
The tablets may be taken spontaneously by dogs, but can also be administered directly into the dog’s mouth or be given with food if necessary.
Contra-indications, warnings, etc
Do not use in case of known hypersensitivity to ACE inhibitors or to any ingredient of the product.
Do not use in any dog that has evidence of cardiac output failure, for example, due to aortic stenosis
No evidence of renal toxicity to benazepril has been observed during clinical trials. However, as is routine in cases of renal insufficiency, it is recommended to monitor plasma urea and creatinine levels.
At the start of the treatment, a decrease of the blood pressure and a transient increase of plasmatic concentrations of creatinine may occur.
On rare occasions, transient signs of hypotension, such as lethargy and ataxia may occur.
Studies in laboratory animals (rats) have shown embryotoxic effects (malformations of the fœtal urinary system) at doses not toxic for the mother.
The safety of the medicinal product has not been studied in pregnant or lactating females. Do not use during pregnancy or lactation. Do not use in breeders.
Interactions with potassium sparing diuretics, like spironolactone, triamteren and amiloride, can not be excluded.
The concurrent administration of potassium-sparing diuretics should only be considered under regular monitoring of plasma potassium.
The association of this product with other anti-hypertensive agents (e.g.: calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effect.
In humans, the association of ACE inhibitors and NSAIDs can lead to reduced anti-hypertensive efficacy or impaired renal function. Therefore concurrent administration with NSAIDs or other medications with hypotensive effect should be considered with care.
The concomitant administration of NSAIDs or ciclosporin requires a survey of the renal function.
Pharmaceutical precautions
Do not store above 30 °C. Store in original package. Any part-used tablet should be returned to the opened blister and used within 3 days.
Keep out of reach of children.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Legal category
POM-V
Packaging Quantities
Cardboard box of 10 blisters x 10 tablets
Further information
In dogs with heart failure, benazepril has been given in combination with digoxin, diuretics and anti-arrhythmic drugs without demonstrable adverse interactions.
Transient and reversible signs of hypotension may appear in case of accidental overdose. Treatment is symptomatic, involving intravenous infusion with warm isotonic saline. Morphologic changes such as hypertrophy or hyperplasia of juxtaglomerular cells, increase of uremia and a weight loss of the heart due to an involution have been observed with doses over 10 mg/kg in healthy dogs.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:Pregnant women should take special care to avoid accidental oral exposure, because ACE inhibitors have been found to affect the unborn child during pregnancy in humans. Wash hands after use. In case of accidental ingestion by children, seek medical advice immediately and show this label or the package leaflet to the doctor.
Marketing authorisation number
Vm 20749/4015.
Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction
Company name: Alstoe Ltd
Address: The Industrial Park
Sheriff Hutton
York
YO60 6RZ
Telephone: 01347 878606
Fax: 01347 878333
Email: info@alstoe.co.uk
Website: www.alstoe.co.uk
Presentation
Flavoured clover shaped scored beige tablet, divisible into halves or quarters. Each tablet contains benazepril(as hydrochloride) 18.42 mg (equivalent to benazepril hydrochloride 20 mg)
Uses
Treatment of congestive heart failure in dogs weighing more than 20 kg.
Dosage and administration
Oral administration: 0.23 mg of benazepril per kg bodyweight per day, equivalent to 0.25 mg of benazepril hydrochloride per kg bodyweight per day, as one administration, with or without a meal.
In case of use of quarters or half tablets: Put the remaining quantity of the tablet back into the blister pocket and use for the next administration.
The dose may be doubled, still administered once daily, if judged clinically necessary and advised by the veterinary surgeon.
The tablets may be taken spontaneously by dogs, but can also be administered directly into the dog’s mouth or be given with food if necessary.
Contra-indications, warnings, etc
Do not use in case of known hypersensitivity to ACE inhibitors or to any ingredient of the product.
Do not use in any dog that has evidence of cardiac output failure, for example, due to aortic stenosis
No evidence of renal toxicity to benazepril has been observed during clinical trials. However, as is routine in cases of renal insufficiency, it is recommended to monitor plasma urea and creatinine levels.
At the start of the treatment, a decrease of the blood pressure and a transient increase of plasmatic concentrations of creatinine may occur.
On rare occasions, transient signs of hypotension, such as lethargy and ataxia may occur.
Studies in laboratory animals (rats) have shown embryotoxic effects (malformations of the fœtal urinary system) at doses not toxic for the mother.
The safety of the medicinal product has not been studied in pregnant or lactating females. Do not use during pregnancy or lactation. Do not use in breeders.
Interactions with potassium sparing diuretics, like spironolactone, triamteren and amiloride, can not be excluded.
The concurrent administration of potassium-sparing diuretics should only be considered under regular monitoring of plasma potassium.
The association of this product with other anti-hypertensive agents (e.g.: calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effect.
In humans, the association of ACE inhibitors and NSAIDs can lead to reduced anti-hypertensive efficacy or impaired renal function. Therefore concurrent administration with NSAIDs or other medications with hypotensive effect should be considered with care.
The concomitant administration of NSAIDs or ciclosporin requires a survey of the renal function.
Pharmaceutical precautions
Do not store above 30 °C. Store in original package. Any part-used tablet should be returned to the opened blister and used within 3 days.
Keep out of reach of children.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Legal category
POM-V
Packaging Quantities
Cardboard box of 10 blisters x 10 tablets
Further information
In dogs with heart failure, benazepril has been given in combination with digoxin, diuretics and anti-arrhythmic drugs without demonstrable adverse interactions.
Transient and reversible signs of hypotension may appear in case of accidental overdose. Treatment is symptomatic, involving intravenous infusion with warm isotonic saline. Morphologic changes such as hypertrophy or hyperplasia of juxtaglomerular cells, increase of uremia and a weight loss of the heart due to an involution have been observed with doses over 10 mg/kg in healthy dogs.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:Pregnant women should take special care to avoid accidental oral exposure, because ACE inhibitors have been found to affect the unborn child during pregnancy in humans. Wash hands after use. In case of accidental ingestion by children, seek medical advice immediately and show this label or the package leaflet to the doctor.
Marketing Authorisation Holder (if different from Distributor)
Sogeval SA
Marketing authorisation number
Vm 20749/4016.
| 
